Kane Biotech (KNE) AI Stock Analysis

• Market Cap: C$5.86M
• Dividend Yield: N/A
• Average Volume (3M): 112.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 181,596,560
• 10 Day Avg. Volume: 120,057
• 30 Day Avg. Volume: 112,955
• PEG Ratio: 0.13
• Price to Book (P/B): -9.04
• Price to Sales (P/S): 7.08
• P/FCF Ratio: -3.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.04 ▲(26.67% Upside)

Kane Biotech's overall stock score is primarily impacted by its poor financial performance, which poses significant risks. Technical analysis supports a bearish outlook, and valuation metrics are unattractive due to ongoing losses. The lack of earnings call and corporate events data limits additional insights, but the existing data indicates a challenging investment environment.

Positive Factors

Patented antimicrobial technology targeting biofilms

Owning patented antimicrobial technologies focused on biofilm control provides a durable competitive moat. Structural demand for biofilm solutions in healthcare, veterinary and industrial markets supports multi-year product adoption, licensing leverage, and differentiation versus commodity competitors.

Diversified revenue channels (sales, licensing, partnerships)

Multiple revenue streams — direct product sales, royalties from licensing, and potential milestone/partner payments — reduce reliance on a single channel. This mix can provide recurring cash inflows and optionality to scale via partners, supporting steadier medium-term revenue resilience.

Improving free cash flow growth

Positive free cash flow growth indicates initial progress toward cash generation, and a FCF-to-net-income near 1 suggests reported losses may be less cash-destructive than they appear. If sustained, this trend supports funding of operations or reduced external financing over the next several quarters.

Negative Factors

Severe revenue decline

A ~69% revenue drop is a structural concern: it pressures gross margins, limits scale economics for R&D and commercialization, and undermines pricing leverage. Sustained revenue attrition over multiple quarters risks loss of market relevance and worsens financing terms.

Negative equity and high leverage

Negative shareholder equity and extreme leverage materially constrain strategic flexibility. High leverage raises refinancing and covenant risks, increases default probability in stress, and can force dilutive capital raises that erode long-term shareholder value and weaken partner confidence.

Ongoing negative operating cash flow and liquidity strain

Persistent negative operating cash flow means core operations are not self-funding, increasing dependence on external financing or asset sales. An OCF-to-net-income of -1.43 signals cash conversion problems that could limit investment in growth and force dilutive financing within the medium term if not reversed.

Kane Biotech Business Overview & Revenue Model

Company Description

Kane Biotech (KNE) is a biotechnology company focused on the development of innovative antimicrobial technologies aimed at addressing biofilm-related challenges across various sectors, including healthcare, veterinary, and industrial applications. The company specializes in creating patented products designed to prevent and treat biofilm infections, which are significant contributors to chronic infections and device-related complications. Kane Biotech's core products include wound care solutions and antimicrobial coatings that enhance the efficacy of medical devices.

How the Company Makes Money

Kane Biotech generates revenue through multiple streams, including the sale of its proprietary antimicrobial products to healthcare providers, veterinary clinics, and industrial clients. The company also engages in licensing agreements, allowing other manufacturers to use its technology in their products, which provides a steady royalty income. Additionally, Kane Biotech may partner with larger pharmaceutical or medical device companies for collaborative research and development projects, which can lead to milestone payments and shared revenue from resulting products. The company’s focus on addressing biofilm-related issues positions it to capitalize on growing market demand in both healthcare and industrial applications.

Kane Biotech Financial Statement Overview

Summary

Kane Biotech is facing significant financial challenges. The income statement shows declining revenue and persistent losses, the balance sheet reflects high leverage and negative equity, and the cash flow statement indicates cash flow constraints. These factors highlight severe financial instability.

Income Statement

Kane Biotech's income statement reveals significant challenges. The company has experienced a substantial decline in revenue growth, with a negative growth rate of -24.27% in the TTM period. Profitability metrics are concerning, with a negative net profit margin of -105.22% and negative EBIT and EBITDA margins, indicating ongoing operational losses. The gross profit margin has also decreased from previous periods, reflecting pressure on cost management. Overall, the income statement highlights severe profitability issues and declining revenue trends.

Balance Sheet

The balance sheet of Kane Biotech shows financial instability. The company has a negative stockholders' equity, leading to a negative debt-to-equity ratio of -11.09 in the TTM period, indicating high leverage and financial risk. The return on equity is positive but misleading due to negative equity. The equity ratio is not calculable due to negative equity, further emphasizing the company's weak financial position. Overall, the balance sheet reflects high leverage and financial distress.

Cash Flow

Kane Biotech's cash flow statement indicates cash flow challenges. The free cash flow growth rate is negative at -31.93% in the TTM period, showing a decline in cash generation. The operating cash flow to net income ratio is negative, reflecting insufficient cash flow to cover net losses. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is marginally covering net losses. Overall, the cash flow statement highlights cash flow constraints and operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	574.87K	2.08M	148.98K	156.73K	1.61M	1.34M
Gross Profit	-131.63K	872.10K	109.47K	1.41M	568.44K	526.86K
EBITDA	-2.77M	-3.71M	-3.23M	-2.95M	-4.25M	-3.65M
Net Income	-1.95M	-3.02M	-5.03M	-3.89M	-4.60M	-3.72M
Balance Sheet
Total Assets	2.74M	2.49M	5.68M	5.62M	6.13M	5.04M
Cash, Cash Equivalents and Short-Term Investments	939.06K	358.81K	749.25K	1.10M	1.15M	1.01M
Total Debt	2.30M	2.29M	9.26M	6.86M	4.71M	2.25M
Total Liabilities	3.53M	4.12M	14.09M	9.76M	7.70M	3.96M
Stockholders Equity	-793.37K	-1.63M	-10.56M	-6.52M	-3.89M	-1.49M
Cash Flow
Free Cash Flow	-3.09M	-4.14M	-3.23M	-3.13M	-2.64M	-4.07M
Operating Cash Flow	-2.99M	-4.11M	-3.22M	-3.04M	-2.29M	-3.94M
Investing Cash Flow	348.00	10.27M	-116.14K	-107.55K	-373.55K	-166.11K
Financing Cash Flow	3.39M	-7.69M	2.98M	3.10M	2.81M	4.28M

Kane Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Positive. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.43 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KNE.

Kane Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APS	51 Neutral	C$5.39M	-0.18	―	―	―	90.81%
MOOD	47 Neutral	C$4.81M	-5.96	-41.36%	―	-50.89%	-32.33%
XRTX	46 Neutral	C$5.67M	-1.24	-96.61%	―	―	-1939.32%
KNE	41 Neutral	C$5.86M	-2.87	―	―	―	―
BIOV	29 Underperform	C$7.29M	-1.12	―	―	―	25.09%

Kane Biotech Corporate Events

Kane Biotech Raises $700,000 in Insider-Led Private Placement

Kane Biotech Inc. has closed a non-brokered private placement with an insider, issuing 14 million common shares at $0.05 per share for gross proceeds of $700,000, with the funds earmarked for working capital and general corporate purposes. The insider-led financing, classified as a related party transaction but exempt from formal valuation and minority approval requirements, remains subject to final TSX Venture Exchange approval and places all new securities under a four-month-plus-one-day hold period, underscoring the company’s continued reliance on equity financing to support its operations and product development.

The most recent analyst rating on (TSE:KNE) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Kane Biotech stock, see the TSE:KNE Stock Forecast page.

Kane Biotech Showcases Advancements in Wound Care at Industry Meeting

Kane Biotech presented new clinical data at the Innovations in Wound Healing Annual Meeting, showcasing advancements in wound care and the efficacy of its products in treating diverse and complex conditions like chronic wounds and Hidradenitis Suppurativa. The presentation underlined the company’s growing role in the wound care industry as it integrates innovative solutions into clinical pathways, strengthening its position as a key player in enhancing patient outcomes and supporting healthcare systems.

The most recent analyst rating on (TSE:KNE) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Kane Biotech stock, see the TSE:KNE Stock Forecast page.

Kane Biotech’s revyve Wound Gel Spray Gains Health Canada Approval

Kane Biotech has announced that its revyve Antimicrobial Wound Gel Spray has received approval from Health Canada, marking a significant regulatory milestone for the company. This approval allows Canadian clinicians and patients access to a new option for managing complex wounds, such as burns and ulcers, and underscores Kane Biotech’s commitment to advancing wound care innovation. The company plans to collaborate with healthcare partners to ensure proper access and education regarding the product’s use, further solidifying its position in the wound care industry.

The most recent analyst rating on (TSE:KNE) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Kane Biotech stock, see the TSE:KNE Stock Forecast page.

Kane Biotech Reports Q3 2025 Results Amid Strategic Progress in Wound Care Market

Kane Biotech announced its third quarter 2025 financial results, revealing a significant decline in revenue and gross profit compared to the previous year, largely due to the termination of key agreements. Despite the financial setbacks, the company is making strides in its strategic initiatives, particularly in the U.S. wound care market. Kane has exceeded enrollment targets for its revyve Antimicrobial Wound Gel U.S. Case Series Studies and presented promising clinical data at major conferences, demonstrating the product’s efficacy in diabetic foot ulcer healing and burn wound infection control. The company is actively working to rebuild its U.S. distributor network and has submitted a 510(k) clearance application to the FDA for its wound cleanser, aiming to expand its market presence and improve patient outcomes.

The most recent analyst rating on (TSE:KNE) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Kane Biotech stock, see the TSE:KNE Stock Forecast page.

Kane Biotech Launches $800,000 Private Placement Offering

Kane Biotech Inc. has announced a non-brokered private placement offering of up to 16 million common shares at $0.05 per share, aiming to raise up to $800,000. The proceeds will be used for working capital and general corporate purposes, with the offering expected to close around December 17, 2025, pending necessary approvals. This move is part of Kane Biotech’s strategy to strengthen its financial position and support its ongoing operations in the wound care industry.

Kane Biotech’s revyve Gel Shows Promising Results in Wound Care

Kane Biotech recently presented promising clinical and pre-clinical data for its revyve Antimicrobial Wound Gel and Gel Spray at major U.S. medical conferences. The data showed significant improvements in diabetic foot ulcer healing and burn wound infection control, with the revyve products outperforming the standard of care by achieving a 97% reduction in wound area within four weeks and complete closure within 12 weeks. These findings highlight revyve’s potential to enhance wound care outcomes and support Kane Biotech’s strategy to impact the U.S. wound care market.